Resource centers

News
Article

Breast Cancer
Updates on Evidence Based Guidelines, controversies, and up-to-date research.

GI Stromal Tumors (GIST)
New therapies, new decisions. We can help.

Recent Videos
2 experts are featured in this series.
With many treatments emerging in the EGFR-mutated lung cancer landscape, sequencing therapy has emerged as a key consideration for these patients.
Although a greater risk of CNS relapse may emerge with immunotherapy-based backbones, toxicities associated with chemotherapy are avoided.
Current FDA expectations may allow patients to return to their community physicians at 2 weeks after administration of anitocabtagene autoleucel.
Based on its mechanism of action, anito-cel may cause fewer instances of cytokine release syndrome and delayed toxicities vs other therapies.
2 experts are featured in this series.
Related Content
Discover the latest breakthroughs in non-small cell lung cancer treatment from the 2025 WCLC, featuring competitive insights from leading experts.

The Battle Between MARIPOSA and FLAURA2 Regimens in NSCLC

ONCOLOGY Staff
December 12th 2025
Article

Discover the latest breakthroughs in non-small cell lung cancer treatment from the 2025 WCLC, featuring competitive insights from leading experts.

Why Sexual and Gender Minority Care is an Oncologic Imperative

Why Sexual and Gender Minority Care is an Oncologic Imperative

Daniel C. McFarland, DO;Charles S. Kamen, PhD, MPH
December 8th 2025
Podcast

Daniel C. McFarland, DO, and Charles S. Kamen, PhD, MPH, focused on cultural humility, nonverbal data collection, and tailored resources to improve care.

Data may support the strong oncologic outcomes of less invasive surgical options for patients with node-negative disease after neoadjuvant chemotherapy.

Less Intensive Surgical Staging Shows Noninferiority in Breast Cancer Trial

Andrea Eleazar, MHS
December 11th 2025
Article

Data may support the strong oncologic outcomes of less invasive surgical options for patients with node-negative disease after neoadjuvant chemotherapy.

Experts highlight considerations for treating patients with oligometastatic kidney cancer, such as differentiating between de novo and recurrent disease.

How to Manage Oligometastatic Kidney Cancer? Insights From IKCS 2025

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD
December 4th 2025
Podcast

Experts highlight considerations for treating patients with oligometastatic kidney cancer, such as differentiating between de novo and recurrent disease.

Nivolumab/AVD Receives FDA Priority Review in Classical Hodgkin Lymphoma

Nivolumab/AVD Receives FDA Priority Review in Classical Hodgkin Lymphoma

Ariana Pelosci
December 11th 2025
Article

The FDA has given a PDUFA date of April 8, 2026, to the nivolumab/AVD regimen for stage III or IV classical Hodgkin lymphoma.

The 60-month local regional recurrence-free rate was 93.2% in the MRI arm vs 95.7% in the no MRI arm among patients with newly diagnosed breast cancer.

Resecting MRI-Detected Disease Doesn’t Improve Outcomes in Early-Stage BC

Tim Cortese
December 11th 2025
Article

The 60-month local regional recurrence-free rate was 93.2% in the MRI arm vs 95.7% in the no MRI arm among patients with newly diagnosed breast cancer.